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While originally described as DNA damage repair agents, recent data suggest a role for poly(ADP-ribose)
polymerase (PARP) enzymes in metabolic regulation by influencing mitochondrial function and oxidative
metabolism. Here we review how PARP activity has a major metabolic impact and the role of PARP-1 and
PARP-2 in diverse metabolic complications.Introduction
Poly(ADP-ribose) polymerases (PARPs) catalyze a reaction in
which the ADP-ribose moiety of NAD+ is transferred to a re-
ceptor amino acid, building poly(ADP-ribose) (PAR) polymers.
PAR polymers are an evolutionarily conserved posttranslational
modification affecting a large array of proteins. However, the
roles of PAR polymers remain uncertain. Recent research sug-
gests they may constitute a protein-binding matrix, and several
PAR-binding motifs have been proposed (Krishnakumar and
Kraus, 2010).
Human PARPs comprise a family of 17 enzymes sharing a
conserved catalytic domain (Krishnakumar and Kraus, 2010).
The first PARP enzyme described, PARP-1, is responsible for
the majority (85%–90%) of PARP activity in the cell, while the
remainder is predominantly PARP-2. Other PARP family mem-
bers bear mutations in the catalytic triad of amino acids that
are crucial for polymer elongation, and these mutations critically
impair their PARylating activity (Krishnakumar and Kraus, 2010).
The function and localization of many PARP family members is
still largely unknown.
PARP-1 and PARP-2 are highly conserved proteins, ubiqui-
tously expressed in mammalian tissues and with predominant
nuclear localization. While low in the basal state, the activity of
PARP-1 and PARP-2 is enhanced allosterically through binding
to several nuclear proteins and to a wide range of DNA or chro-
matin lesions. PARP-1 activity can also be modified through
phosphorylation, acetylation, sumoylation, and ubiquitination.
Importantly, PARP-1 can auto-PARylate itself, which inhibits its
activity, creating an autoregulatory negative feedback (Krishna-
kumar and Kraus, 2010).
PARP-1 and PARP-2 have historically been described as
key DNA damage repair enzymes (Krishnakumar and Kraus,
2010). However, under normal conditions, PARP-1/ and
PARP-2/ mice show similar rates of spontaneous DNA
damage to wild-type littermates, suggesting that the activity of
either PARP-1 or PARP-2 is not essential for viability or DNA
maintenance in the absence of genotoxic stress (Bai et al.,
2011a, 2011b). Rather, these transgenic models have illustrated
that PARP-1 and PARP-2 regulate a plethora of other processes,
including tumorigenesis, inflammation, and cell differentiation
(Krishnakumar and Kraus, 2010). Additionally, the PARP-1/290 Cell Metabolism 16, September 5, 2012 ª2012 Elsevier Inc.and PARP-2/ mouse models also uncovered a major meta-
bolic role for PARP enzymes.
Acute Metabolic Consequences of PARP Activation
NAD+ Metabolism and ATP Crisis
PARP-1 activity constitutes a major NAD+ catabolic activity in
the cell, depleting NAD+ to 10%–20% of its normal levels within
minutes upon DNA damage (Houtkooper et al., 2010). This
unsustainable NAD+ consumption rate forces the cell to synthe-
size NAD+ using salvage pathways in order to maintain cellular
viability. However, NAD+ salvage is an ATP-consuming process
(Houtkooper et al., 2010). Hence, persistent PARP activation
also results in ATP depletion, creating a feedback loop that
can compromise cell survival.
The reduction of NAD+ levels promoted by PARP overacti-
vation is sufficient to impair glycolysis, where NAD+ is a key
cofactor (Houtkooper et al., 2010). Reduction of the glycolytic
rate shuts down amajor source of rapid ATP formation that could
be used for NAD+ resynthesis. In addition, it reduces the flow of
glucose-derived metabolites into the TCA cycle for oxidation,
further compromising energy balance. This decrease in mito-
chondrial ATP production has a critical role in mediating the
apoptotic effects of chronic PARP activation, as illustrated by
the fact that addition of TCA substrates can rescue PARP over-
activation-induced cell death (Ying et al., 2002).
Direct PARylation Effects on Mitochondrial Energy
Production
PARP-1 activation rapidly impairs mitochondrial function (Can˜-
uelo et al., 2012), though it is difficult to dissect whether this
impairment is related to the decreased availability of NAD+,
reduced glycolysis, or to a direct effect of PARP-1 on mitochon-
drial respiration. Recently, elegant experiments showed that
heterologous expression of a truncated, but active version of
PARP-1 containing a mitochondrial localization signal, led to
mitochondrial PAR accumulation and respiratory impairment,
despite elevated glycolytic flux (Niere et al., 2008). This indicates
that increased mitochondrial PARP activity alone is sufficient to
directly impair mitochondrial function, irrespective of glycolytic
rates. However, the significance of mitochondrial PARP activity
in physiological scenarios is far from understood. While classi-
cally regarded as a nuclear protein, both PARP-1 and PARylation
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Therefore, the PARylation of mitochondrial proteins could poten-
tially affect their enzymatic activity. Supporting this hypothesis,
the overexpression of mitochondrial PAR degrading enzymes,
such as PAR glycohydrolase (PARG) or ADP-ribosylhydrolase
3 (ARH3), rescues mitochondrial PARylation and dysfunction
upon PARP-1 activation (Lai et al., 2008; Niere et al., 2008).
These findings would suggest the controversial hypothesis that
direct PARylation events in the mitochondria contribute to the
reduction of respiration rates upon PARP-1 activation. Under-
standing the physiological regulation of mitochondrial PARP
activity and its impact on mitochondrial function will be an inter-
esting field for future investigation.
PARP-1 and PARP-2 as Metabolic Transcriptional
Regulators
PARP-1 localizes to the promoters of actively transcribed genes,
though it only regulates a subset of them, exerting both positive
and negative effects on transcription (Krishnakumar and Kraus,
2010). PARP-1 and PARP-2 act as transcriptional coregulators
by influencing the recruitment of histone acetyltransferases and
corepressors into different transcriptional complexes (Krishna-
kumar and Kraus, 2010). From a metabolic perspective, PARP-
1 and PARP-2 interact with a large number of nuclear receptors
and transcription factors regulating mitochondrial and lipid
oxidation genes, such as PPARg, FOXO1, and ER, among others
(Bai et al., 2007; Krishnakumar and Kraus, 2010; Sakamaki et al.,
2009). In some cases, PARP activation represses their transcrip-
tional activity, for example by impeding correct DNA binding
through direct PARylation of the transcription factors or their
cofactors (Krishnakumar and Kraus, 2010). The PARylation of
transcriptional metabolic regulators remains, however, a vastly
unexplored field. PARP activity can also enhance transcription
via the indirect modification of inhibitory histone marks or the
facilitation of DNA cleavage and transcriptional activation (for
review, see Krishnakumar and Kraus, 2010). PARP-1 may also
exert noncatalytic effects on transcriptional regulation (Sakamaki
et al., 2009), potentially through binding interactions in transcrip-
tional complexes. The molecular mechanisms by which PARP-1
can display both coactivating and corepressing functions are
still elusive.
The Interrelationship of PARP-1, PARP-2, and SIRT1
SIRT1 is an NAD+-dependent type III deacetylase that regulates
oxidative metabolism and global metabolic homeostasis. Phar-
macologically or genetically induced increases in SIRT1 activity
protect against high-fat diet (HFD)-inducedmetabolic damage in
mice. To do so, SIRT1 deacetylates and regulates the activity
of a number of crucial enzymes and transcriptional regulators
(Houtkooper et al., 2010). A priori, SIRT1 has a KM for NAD
+
that lies within the range of the most commonly reported total
intracellular NAD+ concentrations (Houtkooper et al., 2010).
This could explain why most strategies designed to increase
intracellular NAD+ generally resulted in higher SIRT1 activity
(Houtkooper et al., 2010). These observations suggest that
NAD+ bioavailability may control SIRT1 activity, leading to the
hypothesis that SIRT1 might act as a metabolic sensor that
fine tunes transcriptional programs to the use of different ener-
getic substrates. However, the interpretation of NAD+-related
data should be taken cautiously, as most techniques used todate fail to provide complete information on subcellular NAD+
compartmentalization or to differentiate between free and pro-
tein-bound NAD+.
TheNAD+dependence of SIRT1 andPARP-1 activities promp-
ted the hypothesis that these enzymes could compete for a
limitedNAD+pool. Indeed,SIRT1andPARP-1activities can influ-
ence each other in different cellular and in vivo models. The
mechanisms for this reciprocal regulation, however, may be dif-
ferent. The KM of PARP-1 for NAD
+ is five to ten times lower than
intracellular NAD+ levels (Houtkooper et al., 2010). Therefore, it is
unlikely that SIRT1 activity decreases NAD+ concentrations to
levels that are limiting for PARP-1 activity. Instead, SIRT1 has
been shown to reduce PARP activity in certain contexts via direct
binding and deacetylation of PARP-1 (Rajamohan et al., 2009).
PARP-1, in contrast, is an avid NAD+ consumer (Houtkooper
et al., 2010). Therefore PARP-1 may compromise SIRT1 activity
by reducing NAD+ bioavailability. This idea is further sup-
ported by recent observations indicating that pharmacological
or genetic reductions of PARP activity increase intracellular
NAD+ levels and enhance SIRT1 activity (Bai et al., 2011b).
Potentially, PARP-1 could also influence SIRT1 activity through
direct PARylation. However, SIRT1 is not PARylated inmyotubes
when PARP-1 is activated in response to oxidative stress (Bai
et al., 2011b). Therefore, PARP-1 most likely influences SIRT1
activity indirectly through the modulation of NAD+ levels. Inter-
estingly, in contrast to SIRT1, neither cytoplasmic SIRT2, nor
mitochondrial SIRT3 activities were increased by PARP-1 dele-
tion (Bai et al., 2011b). This suggests that the increase in NAD+
promoted byPARP-1 deletionmight be restricted to the nucleus,
where PARP-1 predominantly resides. Accordingly, it will be im-
portant in future studies to monitor the activity of the other
nuclear sirtuins, SIRT6 and SIRT7, upon altered PARP-1 activity.
PARP-2 deletion also enhances cellular SIRT1 activity, appar-
ently without direct impact on NAD+ levels (Bai et al., 2011a).
Instead, PARP-2 deletion resulted in a 2- to 3-fold increase in
SIRT1 levels, both in cultured cells and mouse tissues (Bai
et al., 2011a). PARP-2 binds to the SIRT1 promoter in the basal
state and represses its transcriptional activity (Bai et al., 2011a).
Hence, PARP-2 deletion relieves the repression on the SIRT1
promoter, increasing basal SIRT1 mRNA and protein levels
(Bai et al., 2011a). Therefore, the higher SIRT1 activity observed
in PARP-2/mice is not necessarily related to increased NAD+
levels, but to increased SIRT1 expression.
The negative correlation of PARP and SIRT1 activities is also
found in physiological scenarios. PARP activity increases upon
HFD, while SIRT1 activity is lower (Bai et al., 2011b). In contrast,
PARP activity is lower in muscle after an overnight fast, when
SIRT1 activity is high (Bai et al., 2011b). Interestingly, higher
PARP activity is observed in aged rodent tissues, leading to
decreased NAD+ content and limited SIRT1 activity (Braidy
et al., 2011). These observations suggest that physiological vari-
ations in PARP activity may have a significant impact on SIRT1.
Metabolic Actions of PARP-1 and PARP-2 in Health
and Disease
Regulation of Energy Intake
Several observations suggest that PARP-1may influence feeding
behavior. PARP-1 deletion in two different mouse strains led to
increased food intake (Bai et al., 2011b; Devalaraja-NarashimhaCell Metabolism 16, September 5, 2012 ª2012 Elsevier Inc. 291
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dian entrainment of feeding behavior (Asher et al., 2010). In
contrast, the deletion of PARP-2 does not lead to significant
changes in food intake or daily behavior (Bai et al., 2011a). This
indicates that PARP-1might influence food intake in two different
ways: either through PARylation of substrates that PARP-2 does
not target or through mass disturbance of NAD+ metabolism,
which determines circadian behavior (Nakahata et al., 2009).
Regulation of Mitochondrial Biogenesis
and Energy Expenditure
Both PARP-1/ and PARP-2/mice display enhanced energy
expenditure (EE) (Bai et al., 2011a, 2011b). This effect could
derive, at least in part, from an increase in SIRT1 activity, as
described above. SIRT1 can regulate EE by deacetylating and
activating master transcriptional regulators of oxidative metabo-
lism, such as PGC-1a and the FOXO family of transcription
factors (Houtkooper et al., 2010). Consistently, PARP-1/ and
PARP-2/ muscles showed a marked deacetylation of PGC-
1a and FOXO1, which was linked to enhanced mitochondrial
biogenesis and a more oxidative profile of muscle fibers (Bai
et al., 2011a, 2011b).
The brown adipose tissue (BAT) of PARP-1/ mice is also
characterized by increased mitochondrial content (Bai et al.,
2011b). Physiologically, this renders PARP-1/ mice more
able to maintain body temperature when exposed to cold. Inter-
estingly, the deletion of PARP-2 does not influence mitochon-
drial biogenesis in BAT, despite increasing SIRT1 content (Bai
et al., 2011a). It is possible that there are either limiting NAD+
levels in the BAT of PARP-2/ versus PARP-1/ mice or that
there are additional mediators of the PARP-1/ phenotype
other than the SIRT1/PGC-1a axis.
Regulation of Adipogenesis, Fat Deposition
and Body Weight
The deletion of either PARP-1 or PARP-2 in C57Bl/6 mice
protects against age- and HFD-induced body weight (BW) gain
(Bai et al., 2011a, 2011b; Erener et al., 2012b). This phenotype
is explained, at least in part, by their enhanced EE. However,
a direct regulation of fat deposition by PARP enzymes may
also contribute.
PARP-1 activity is necessary for white adipocyte differentia-
tion, and increased PARylation can be observed in differentiating
3T3-L1 adipocytes (Erener et al., 2012a). PARP-1 is recruited to
PPARg target genes in a PAR-dependent manner, allowing sus-
tained expression of PPARg and its target genes (Erener et al.,
2012a). Accordingly, PARP-1/ mice display reduced fat
mass deposition (Bai et al., 2011b; Erener et al., 2012b). The
histological analysis of white adipose tissue (WAT) from PARP-
1/ mice revealed a dramatic decrease in adipocyte size (Ere-
ner et al., 2012b). In addition, adipose stem cells from PARP-
1/ mice displayed lower expression of PPARg target genes
upon differentiation, as well as a reduced ability to accumulate
triglycerides (Erener et al., 2012b). Therefore, PARP-1 acts as
a positive regulator of adipogenesis and adipocyte function.
Fully supporting this, transgenic mice harboring an ectopic inte-
gration of human PARP-1 (hPARP-1 mice) display enhanced
adiposity (Mangerich et al., 2010). Interestingly, the lack of
PARP-2 also hampers the adipocytic differentiation of embry-
onic fibroblasts and 3T3-L1 cells (Bai et al., 2007). Similarly to
PARP-1, PARP-2 binds and positively regulates PPARg-driven292 Cell Metabolism 16, September 5, 2012 ª2012 Elsevier Inc.promoters (Bai et al., 2007), enhancing adipogenic differentiation
and fat deposition.
The activation of SIRT1may also contribute to downregulation
of PPARg activity and reduced fat storage in PARP-1- and
PARP-2-deficient models. SIRT1 decreases adiposity through
various mechanisms, including the reduction of PPARg tran-
scriptional activity by promoting the direct docking of tran-
scriptional corepressors (reviewed in Houtkooper et al., 2010).
An interesting question is whether reduced WAT depots could
potentially lead to lipid redistribution. Indeed, a recent report
identified increased fat deposition in the livers of PARP-1/
mice when fed a HFD (Erener et al., 2012b). Interestingly,
PARP-1 is poorly expressed in the liver, and its deletion does
not seem to have a major influence on hepatic expression of
mitochondrial and lipid oxidation genes (Bai et al., 2011b),
potentially creating a permissive scenario for lipid deposition.
These observations, however, are at odds with the notion that
PARP-1 deficiency dampens PPARg activity and with the lower
BW of PARP-1/ mice. Further research will be required to
clarify this apparent discrepancy.
Strikingly, PARP-1 deletion on an SV129 background renders
mice susceptible to obesity (Devalaraja-Narashimha andPadani-
lam, 2010). As discussed recently (Bai et al., 2011b), however,
a wealth of pharmacological, physiological and genetic data
supports the observations in the C57Bl/6 strain. The particular
reasons why PARP-1 deletion in a SV129 background rendered
an opposite phenotype are unknown.
PARP-1 and PARP-2 in Glucose Metabolism
and Insulin Sensitivity
PARP-1/ and PARP-2/ mice display increased glucose
clearance in response to an insulin tolerance test (Bai et al.,
2011a, 2011b). The ability of PARP-1 and PARP-2 deletion to
enhance the muscle oxidative profile might contribute to this
phenotype, as oxidative muscle fibers are more insulin sensitive
than glycolytic fibers. In addition, the greater potential to oxidize
fat might prevent the chronic deposition of lipid species detri-
mental for insulin action.
While enhanced insulin sensitivity is generally correlated with
better glucose tolerance, PARP-2/ mice were markedly glu-
cose intolerant when fed a HFD (Bai et al., 2011a). This glucose
intolerant phenotype stems from pancreatic b cell dysfunction.
Upon HFD, the pancreatic b cell mass increases in order to com-
pensate for peripheral insulin resistance. In PARP-2/ mice,
however, this hyperplastic response is impaired. PARP-2/
mice display smaller b cell islets and reduced insulin content, re-
sulting in a blunted ability to release insulin after a glucose load
(Bai et al., 2011a). The mechanism by which PARP-2 deletion
impairs b cell proliferation may involve constitutive SIRT1 activa-
tion, which leads to FOXO1 deacetylation and activation (Bai
et al., 2011a). FOXO1, in turn, represses b cell proliferation and
development. Yet why is pancreatic dysfunction not observed
in PARP-1/mice? From one side, the actions of PARP-2might
be noncatalytic. Another likely possibility is that PARP-1 dif-
ferentially affects NAD+ homeostasis and SIRT1 activity in dif-
ferent tissues, depending on its basal activity. Alternatively, other
actions specifically triggered by PARP-1 deficiency might pre-
vent b cell dysfunction.
In fact, a major role for PARP-1 in b cell physiology was re-
vealed by experiments determining howPARP inhibitors improve
Table 1. Key Observations on How PARP-1 and PARP-2
Intertwine with Metabolic Homeostasis
Model Phenotype Reference
PARP-1
Knockout in
C57Bl/6 mice
Altered circadian
food entrainment
behavior
(Asher et al., 2010)
Knockout in
C57Bl/6 mice
Increased energy
expenditure and
mitochondrial
biogenesis
(Bai et al., 2011b)
Knockout in
C57Bl/6 mice
Lower body weight
gain when fed
high-fat diets
(Bai et al., 2011b;
Erener et al., 2012b)
Knockout in
C57Bl/6 mice
Both higher and lower
glucose tolerance
have been reported
(Bai et al., 2011b;
Erener et al., 2012b)
Knockout in
C57Bl/6 mice
Higher hepatic lipid
accumulation
(Erener et al., 2012b)
Knockout in
C57Bl/6 mice
Increased NAD+
content and SIRT1
activity
(Bai et al., 2011b)
Knockout in
129/SvImJ mice
Enhanced
susceptibility
to high-fat diet-
induced obesity
(Devalaraja-Narashimha
and Padanilam, 2010)
Knockout in
129SVxC57Bl/6
mice
Protection against
streptozotocin-
induced diabetes
(Burkart et al., 1999)
Mice harboring an
ectopic integration
of human PARP-1
Premature
development of
age-associated
pathologies
(Mangerich et al., 2010)
Mice harboring an
ectopic integration
of human PARP-1
Enhanced adiposity
Mice harboring an
ectopic integration
of human PARP-1
Glucose intolerance
Knockdown in
HEK293T cells
Enhanced mitochondrial
gene expression and
respiration
(Bai et al., 2011b)
Knockdown in
HEK293T cells
Higher NAD+ content
and SIRT1 activity
Knockdown in
3T3-L1 adipocytes
Reduced adipocyte
differentiation and
PPARg-dependent
gene expression
(Erener et al., 2012a)
PARP-2
Knockout in
C57Bl/6 mice
Increased energy
expenditure and
mitochondrial
biogenesis
(Bai et al., 2011a)
Knockout in
C57Bl/6 mice
Lower body weight
when fed high-
fat diets
Knockout in
C57Bl/6 mice
Glucose intolerance
despite high insulin
sensitivity
Table 1. Continued
Model Phenotype Reference
Knockout in
C57Bl/6 mice
Decreased pancreatic
b cell mass
Knockout in
C57Bl/6 mice
Lower WAT mass
on chow diet
(Bai et al., 2007)
Knockdown in
C2C12 myotubes
Increased SIRT1
levels and
mitochondrial
gene expression
(Bai et al., 2011a)
Knockout murine
embryonic
fibroblasts
Reduced adipocyte
differentiation and
PPARg-dependent
gene expression
(Bai et al., 2007)
PARP Inhibition
C2C12 myotubes
(PJ34; 1 mM)
Enhanced
mitochondrial gene
expression and
respiration
(Bai et al., 2011b)
Partially
depancreatized
rats (0.5 g/kg NAM
and 0.05 g/kg
3-ABA per day)
Better b cell
regeneration and
prevention of
diabetes mellitus
(Yonemura et al.,
1984)
Mice (PJ34;
10 mg/kg/day)
Better lipid metabolic
profile after a 5 day
treatment
(Bai et al., 2011b)
Physiology
High-fat diet Enhanced PARP
activity and PARP-1
protein levels
(Bai et al., 2011b)
Aging Enhanced PARP
activity
(Braidy et al., 2011)
Fasting Lower PARP activity (Bai et al., 2011b)
The table summarizes how changes in PARP-1 or PARP-2 activity influ-
ence metabolism and vice versa.
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promoting faster b cell regeneration and normalization of blood
glucose (Yonemura et al., 1984). Subsequent studies demon-
strated that PARP-1/ mice are resistant to the development
of streptozotocin-induced diabetes andmaintain normal pancre-
atic insulin content and islet morphology (Burkart et al., 1999).
The normal pancreatic b cell function of PARP-1/ mice in the
basal state, however, suggests the detrimental effect of PARP-
1 activity in the pancreas is only apparent in situations of oxida-
tive stress.
Future Perspectives
Most classical work characterized PARP-1 and PARP-2 as
genome integrity maintenance enzymes. Several findings, how-
ever, highlight novel roles for PARP-1 and PARP-2 in metabolic
regulation (summarized in Table1). PARP activation impacts on
cellular metabolism through diverse mechanisms, including
alterations in NAD+ metabolism, direct PARylation events and
transcriptional reprogramming of the cell. In general, PARP inhi-
bition enhances oxidative metabolism and mitochondrial con-
tent. This suggests that reducing PARP activity might preventCell Metabolism 16, September 5, 2012 ª2012 Elsevier Inc. 293
Figure 1. Metabolic Consequences of PARP
Activation or Inhibition
Diverse physiological situations—such as high-
fat feeding, oxidative stress, spontaneous DNA
damage, and aging—increase PARP activity. In
the short term, PARP activity is required for effi-
cient DNA repair, but can also lead to NAD+
depletion, consequently slowing down ATP pro-
duction. PARP-1 and PARP-2 might also directly
affect ATP production through direct PARylation of
enzymes, as has been proposed for mitochondrial
proteins. When prolonged, the effects of PARP
activity on transcriptional regulators can compro-
mise the maintenance of mitochondrial function
and, as evidenced by transgenic models, might
enhance susceptibility to age-related diseases
and alterations in glucose metabolism. In contrast,
nutrient deprivation decreases PARP activity. The
evidence from pharmacological or genetic reduc-
tions in PARP activity indicates that lower PARP
activity increases NAD+ bioavailability and en-
hances mitochondrial biogenesis. These changes
confer protection against age and diet-induced
body-weight gain. These potential benefits of
PARP inhibition need to be balanced with the
detrimental effects on pancreatic b cell function
caused by PARP-2 deletion, as well as with the
eventual possibility for detrimental effects on
chromosome stability.
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impaired mitochondrial function (Figure 1). In line with this,
a gain of function model for PARP-1, the hPARP-1 mice, dis-
played premature development of age-associated pathologies,
enhanced adiposity, and glucose intolerance (Mangerich et al.,
2010). However, we will need to evaluate the feasibility of long-
term inhibition of PARP activity without a negative impact
on genomic stability. Possible strategies to limit potential side
effects on DNA damage or b cell dysfunction could rely on deter-
mining the minimum level of PARP inhibition required to reach
therapeutic metabolic effects and on the design of specific
inhibitors for PARP-1 and PARP-2. Importantly, while we have
focused on PARP-1 and PARP-2, we need to emphasize that
other PARP family members can also have important metabolic
functions (Table S1 available online), further emphasizing the
need for specific PARP inhibitors to elicit selective metabolic
responses. Finally, most of the in vivo data gathered to date
comes from germline PARP-1 or PARP-2 deletion. The genera-
tion of tissue-specific PARP deficient models will allow us to
dissect the key tissues that should be pharmacologically tar-
geted to achieve optimal metabolic outcomes.
Another challengewill be elucidation of the key effectorsmedi-
ating the long-term benefits of PARP inhibition. While SIRT1
activation is a major candidate, PARP inhibition triggers both
acute and transcriptional effects that are SIRT1-independent
(Bai et al., 2011a, 2011b). Our knowledge of direct PARylation294 Cell Metabolism 16, September 5, 2012 ª2012 Elsevier Inc.events on metabolic regulators is still
weak. Of note, it will be interesting to
examine which metabolic effects of
PARP inhibition are mimicked by the
activation of PAR degrading enzymes. In
conclusion, PARP inhibition holds prom-
ising possibilities for the treatment ofmetabolic damage, but achieving healthy aging through PARP-
based therapies will require further understanding of PAR
biology and fine-tuning the dynamics and specificity of PARP
inhibitors.
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